Iron deficiency, platelets and thromboembolism in cancer patients

Iron Deficiency, Platelet Phenotype and Thromboembolism in Cancer Patients - ThromboCa

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-002981-11-AT

Enrollment

Registered

2013-09-09

Start date

2013-09-24

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer, iron deficiency MedDRA version: 16.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 16.0 Level: PT Classification code 10022970 Term: Iron deficiency System Organ Class: 10027433 - Metabolism and nutrition disorders

Interventions

Trade Name: Ferinject Product Name: ferric carboxymaltose Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ferric carboxymaltose CAS Number: 9007-72-01 Current Sponsor c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: newly diagnosed colorectal cancer iron deficiency Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 84 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: hemoglobin<9g/dL ongoing chemotherapy therapy which influences platelets blood transfusion or iron therapy within 30 days befor study entry

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the effect of iron therapy on platelet counts in patients with colorectal cancer and iron deficiency;Secondary Objective: To evaluate the effect of iron therapy on platelet activity and growth factors in patients with colorectal cancer and iron deficiency;Primary end point(s): drop in platelet counts>10%;Timepoint(s) of evaluation of this end point: week 2	—

Secondary

Measure	Time frame
Secondary end point(s): platelet activation, platelet aggregation, p-selectin, TPO, EPO, Interleukin-6/3/11;Timepoint(s) of evaluation of this end point: week 2	—

Countries

Austria

Contacts

Public ContactClinical trial information

Medical University of Vienna, Department for Gastroenterology

00431404004735

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026